D G Kieback

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Liposomal Doxorubicin Hcl, Metastatic Breast Cancer, Oncology +8

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 829 citations

Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

Peter Reichardt, Gϋnter von Minckwitz, Peter Thuss‐Patience et al. · Annals of Oncology · 2003 · 236 citations · Full text

Metastatic Breast Cancer, Oncology, Breast Oncology +7

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

Claire F. Verschraegen, Tally Levy, Andrzej P. Kudelka et al. · Journal of Clinical Oncology · 1997 · 135 citations

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

A P Kudelka, Tally Levy, Claire F. Verschraegen et al. · PubMed · 1997 · 131 citations

Squamous Cell Cancer, Retinal Hemorrhage, Cervical Cancer +14